Honokiol

別名：NSC 293100

製品コード：S2310 純度：99.88%

Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

CAS No. 35354-74-6

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
10mg	JPY 22000	国内在庫あり
25mg	JPY 37000	国内在庫あり
1g	JPY 280500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（30）

カスタマーフィードバック2例

製品安全説明書

現在のバッチを見る：純度： 99.88%

99.88

Honokiol関連製品

関連製品	Puromycin 2HCl Staurosporine (STS) Cyclosporin A Oligomycin A Geldanamycin Geneticin (G418 Sulfate) Nigericin sodium salt STZ (Streptozotocin) Cephalomannine Sodium Monensin (NSC 343257) 10-Deacetylbaccatin-III Pirarubicin Hygromycin B Embelin Roxithromycin	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library PI3K/Akt Inhibitor Library Apoptosis Compound Library Cell Cycle compound library NF-κB Signaling Compound Library	もっと見る

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
human SH-SY5Y cells	Function assay	10 μM	30 mins	Neuroprotective activity in human SH-SY5Y cells assessed as inhibition of CHP and TBHP-induced cell death at 10 uM incubated for 30 mins prior to challenge measured after 3 hrs by MTT assay	22142539
HUVEC cells	Function assay	20 μM	24 h	Antimigratory activity against human HUVEC cells at 20 uM after 24 hrs by wound-healing assay	21853991
HEK293 cells	Function assay		24-48 h	Agonist activity at human RXR-alpha expressed in HEK293 cells coexpressing with pCMX-beta-gal after 24 to 48 hrs by luciferase reporter gene assay	24959987
human HepG2 cells	Proliferation assay		24 h	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay, IC50=16.5 μM	21853991
human HT-29 cells	Cytotoxicity assay		72 h	Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay, IC50=13.24 μM	22533983
human A549 cell	Cytotoxicity assay		24 h	Cytotoxicity against human A549 cells after 24 hrs by MTS assay, IC50=12.51 μM	22533983
human SPC-A1 cells	Proliferation assay			Antiproliferative activity against human SPC-A1 cells by MTT assay, IC50=36.1 μM	19589678
human A2780 cells	Proliferation assay			Antiproliferative activity against cisplatin-sensitive human A2780 cells by MTT assay, IC50=30.5 μM	19589678
Vero cells	Cytotoxicity assay			Cytotoxicity against Vero cells, IC50=22.5 μM	16722664
human K562 cells	Proliferation assay			Antiproliferative activity against human K562 cells by MTT assay, IC50=21.1 μM	19589678
Hep-G2 cells	Cytotoxicity assay			Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined, IC50=16.5 μM	15582432
human PBM cells	Cytotoxicity assay			Cytotoxicity against human PBM cells, IC50=16.1 μM	17587572
HEK293 cells	Function assay			Agonist activity at RXRalpha in HEK293 cells assessed as transcriptional activation after 48 hrs by luciferase reporter gene assay, EC50=11.8 μM	20695472
human CEM cells	Cytotoxicity assay			Cytotoxicity against human CEM cells, IC50=10.9 μM	17587572
human A549 cells	Cytotoxicity assay			Cytotoxicity against human A549 cells after 72 hrs by MTS assay, IC50=7.75 μM	22533983
human UACC-903 cells	Cytotoxicity assay			Cytotoxicity against human UACC-903 cells after 24 hrs by MTS assay, IC50=7.45 μM	22533983
Vero E6 cells	Function assay			Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA, EC50=6.5 μM	17663539
human UACC-903 cells	Cytotoxicity assay			Cytotoxicity against human UACC-903 cells after 72 hrs by MTS assay, IC50=5.1 μM	22533983
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Targets

Akt-phosphorylation ^[1]

MEK ^[8]

In Vitro
In vitro	Honokiol shows pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma and colon cancer cell lines. Honokiol is effective on inducing apoptosis in SVR angiosarcoma cells. Treatment of SVR cells with honokiol causes decreased phosphorylation of MAP kinase, akt, and c-src. In addition, honokiol potentiates TRAIL-mediated apoptosis, and honokiol cytotoxicity is partially abrogated by neutralizing antibodies to TRAIL. Honokiol also has direct antiangiogenic activity, in that honokiol blocks the phosphorylation and rac activation due to VEGF-VEGFR2 interactions. ^[1] Honokiol causes apoptosis in CLL cells through activation of caspase 8, followed by caspase 9 and 3 activation. Honokiol prevents interleukin-4-mediated survival of CLL cells, and potentiats the cytotoxicity of CB-1348, FaraA, and 2-CdA. ^[3] Honokiol kills myeloma cells from relapsed patients at doses that does not kill PBMCs. Caspase 3, 7, 8, and 9 are induced by honokiol treatment, as well as PARP cleavage. ^[2] Honokiol is found to induce apoptosis in the colon cancer cell lines RKO. ^[4] Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. ^[5] Honokiol may act as a potent anti-inflammatory agent with multipotential activities due to an inhibitory effect on the PI3K/Akt pathway. ^[6]
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	p-EGFR / p-AKT / p-STAT3 / p-ERK / p-GSK3α/β / Bax / p-pRb / p-BAD / IκBα / CDK2 / CDK4 / Cyclin D1 p-Lyn / Lyn / p-PI3K		27458163
	Immunofluorescence	Vimentin / Occludin IκBα / NF-κB p65		24508063

In Vivo
In Vivo	Honokiol is highly effective against SVR angiosarcoma in nude mice. ^[1] Honokiol inhibits the growth of RKO cells in murine xenografts. ^[4] Honokiol prevents the growth of MDA-MD-231 breast cancer cells in murine xenografts. ^[7]

参考
[1] Bai X, et al. J Biol Chem, 2003, 278(37), 35501-35507. [2] Ishitsuka K, et al. Blood, 2005, 106(5), 1794-800. [3] Battle TE, et al. Blood, 2005, 106(2), 690-697. [4] Wang T, et al. World J Gastroenterol, 2004, 10(15), 2205-2208. [5] Ahn KS, et al. Mol Cancer Res, 2006, 4(9), 621-633. [6] Kim BH, et al. Acta Pharmacol Sin, 2008, 29(1), 113-122. [7] Wolf I, et al. Int J Oncol, 2007, 30(6), 1529-1537. [8] Haifeng Zhai, et al. Eur J Pharmacol. 2005 Jun 1;516(2):112-7. + 展開

参考

+ 展開

化学情報

分子量	266.334	化学式	C₁₈H₁₈O₂
CAS No.	35354-74-6	SDF	Download Honokiol SDFをダウンロードする
Smiles	C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 53 mg/mL ( (198.99 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo Batch: Add solvents to the product individually and in order.					投与溶液組成計算機
	Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	2.0mg/ml (7.51mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.	投与溶液組成計算機
Clear solution	5% DMSO 1 95% Corn oil	0.5mg/ml (1.88mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	2%DMSO 1 40%PEG300 2 2%Tween80 3 56%ddH2O	2.0mg/ml (7.51mM)	Taking the 1 mL working solution as an example, add 20 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 20 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 560 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):